Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Scientific Reports|October 4, 2017
Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkersBahil Ghanim, Sebastian Hess, Pietro Bertoglio, et al.
Histopathology|March 15, 2020
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesotheliomaAgnes Bilecz, Paul Stockhammer, Dirk Theegarten, et al.
World Journal of Surgical Oncology|February 18, 2024
C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancerChristian Lang, Zsolt Megyesfalvi, Andras Lantos, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Science Immunology|March 28, 2025
An aging bone marrow exacerbates lung fibrosis by fueling profibrotic macrophage persistenceAsma Farhat, Mariem Radhouani, Florian Deckert, et al.
Elife|January 13, 2022
ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathologyRiem Gawish, Philipp Starkl, Lisabeth Pimenov, et al.
Nature Medicine|May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trialMatthias Preusser, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|July 10, 2019
Tenascin-C increases lung metastasis by impacting blood vessel invasionsZhen Sun, Inés Velázquez-Quesada, Devadarssen Murdamoothoo, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialRupert Bartsch, Maximilian Marhold, Javier Garde-Noguera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2020
Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma SubgroupChristine Pirker, Agnes Bilecz, Michael Grusch, et al.
Pageof 6